🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseGLP-1 hepatoprotection — looking for input Page 6

GLP-1 hepatoprotection — looking for input

emma_london Sat, Jan 3, 2026 at 5:22 PM 32 replies 1,569 viewsPage 6 of 7
DerekSJ_a1c
Member
378
1,678
Aug 2024
San Jose, CA
Jan 6, 2026 at 6:13 PM#26
wendy_avl said:
Practical: whatever you change, write down the date and the reason.

This is where I part company with the consensus forming above. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Jan 6, 2026 at 11:13 PM
39 12adam_van, Dr.SurgeonPGH, rachel_ABQ and 36 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Jan 7, 2026 at 12:50 AM#27
wendy_avl said:
Practical: whatever you change, write down the date and the reason.

Correct, and worth adding that it is reversible. Nothing being described here is a one-way door, which changes how cautious it is reasonable to be.

Last edited: Jan 7, 2026 at 6:50 AM
40 13roxy_nash, tony_orlando, Dr.NephBHM_UK and 37 others
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
Jan 7, 2026 at 7:27 AM#28
wendy_avl said:
Practical: whatever you change, write down the date and the reason.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

41 14RunnerRach, TrialNerd_Beth, HPLC_Greg and 38 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Jan 7, 2026 at 2:04 PM#29

Clinical perspective, offered as context rather than as advice. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

42 15AussieAnna, BethLabQueen, ChrisMacros and 39 others
Reply Quote Save Share Report
emma_london
Member
312
1,456
Oct 2024
London, UK
Jan 7, 2026 at 8:41 PM#30

Reporting back.

Reporting back with a partial result, because a partial result is still better than silence. Two of the three things suggested helped; I cannot separate them and I am not going to pretend otherwise.

14 12julia.endo, JessicaM_2024, TomFromTexas and 11 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register